Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY(®) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

INTRODUCTION: Ozoralizumab (OZR), a tumor necrosis factor alpha (TNFα) inhibitor, is a NANOBODY(®) compound that binds to TNFα and human serum albumin. The main objective of this study was to analyze the pharmacokinetics (PK) of the drug and its correlation with clinical efficacy in patients with rh...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Chino, Yukihiro, Kawanishi, Masafumi, Nakanishi, Megumi, Watase, Hirotaka, Mano, Yoko, Sato, Yuri, Uchida, Saeko, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099673/
https://www.ncbi.nlm.nih.gov/pubmed/37055803
http://dx.doi.org/10.1186/s13075-023-03036-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099673/
https://www.ncbi.nlm.nih.gov/pubmed/37055803
http://dx.doi.org/10.1186/s13075-023-03036-4

Ejemplares similares